Optimizing the delivery of care to patients with advanced epithelial ovarian cancer receiving first-line maintenance treatment with a poly(ADP-ribose) polymerase inhibitor

BACKGROUND: Despite the demonstrated clinical benefits of poly(ADP-ribose) polymerase inhibitors (PARPis), up to 25% of newly diagnosed patients are nonadherent. To maximize clinical outcomes, there is a need to identify best practices used at centers of excellence that treat patients with advanced epithelial ovarian cancer (aEOC) with PARPis. MATERIALS AND METHODS: A qualitative initiative was undertaken in which healthcare professionals (HCPs) from select centers of excellence in the European Union and North America were invited to complete an online survey, be interviewed, and participate in a virtual workshop. The 15-item survey asked questions about the factors comprising PARPi models of care at their center, the typical patient journey, and current treatment challenges. The interview and workshop were intended to gain additional insights and to further define the key components of care models, as well as factors contributing to long-term therapeutic success. RESULTS: Twelve centers of excellence, six in the European Union and six in North America, participated. Five factors were identified as contributing to PARPi models of care at the participating centers of excellence: (1) supportive infrastructure to optimize patient care, (2) best communication practices for HCPs, (3) HCP education and support to optimize patient care, (4) PARPi maintenance treatment initiation to support long-term adherence, and (5) PARPi maintenance treatment adherence and continuation. CONCLUSION: The creation of a compassionate, supportive healthcare environment is essential to maximizing the likelihood of patients with aEOC initiating, adhering to, and continuing with first-line maintenance treatment with a PARPi.